JP2022513721A - 筋萎縮性側索硬化症における治療的介入を導くためのニューロフィラメントタンパク質 - Google Patents

筋萎縮性側索硬化症における治療的介入を導くためのニューロフィラメントタンパク質 Download PDF

Info

Publication number
JP2022513721A
JP2022513721A JP2021531983A JP2021531983A JP2022513721A JP 2022513721 A JP2022513721 A JP 2022513721A JP 2021531983 A JP2021531983 A JP 2021531983A JP 2021531983 A JP2021531983 A JP 2021531983A JP 2022513721 A JP2022513721 A JP 2022513721A
Authority
JP
Japan
Prior art keywords
therapeutic agent
patient
biological sample
neurofilament
level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2021531983A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020117772A5 (https=
JP2022513721A5 (https=
Inventor
トビー アーロ ファーガソン，
ダニエル リーゼッタ グラハム，
スティーブ サン－ウー ハン，
アレクサンダー リード ヴィンセント マッキャンベル，
ジュリオ スルベック－トマシー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen MA Inc
Original Assignee
Biogen MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen MA Inc filed Critical Biogen MA Inc
Publication of JP2022513721A publication Critical patent/JP2022513721A/ja
Publication of JPWO2020117772A5 publication Critical patent/JPWO2020117772A5/ja
Publication of JP2022513721A5 publication Critical patent/JP2022513721A5/ja
Priority to JP2024072811A priority Critical patent/JP2024096258A/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3525—MOE, methoxyethoxy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y115/00—Oxidoreductases acting on superoxide as acceptor (1.15)
    • C12Y115/01—Oxidoreductases acting on superoxide as acceptor (1.15) with NAD or NADP as acceptor (1.15.1)
    • C12Y115/01001—Superoxide dismutase (1.15.1.1)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
JP2021531983A 2018-12-06 2019-12-03 筋萎縮性側索硬化症における治療的介入を導くためのニューロフィラメントタンパク質 Withdrawn JP2022513721A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024072811A JP2024096258A (ja) 2018-12-06 2024-04-26 筋萎縮性側索硬化症における治療的介入を導くためのニューロフィラメントタンパク質

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862776253P 2018-12-06 2018-12-06
US62/776,253 2018-12-06
US201962840431P 2019-04-30 2019-04-30
US62/840,431 2019-04-30
US201962842063P 2019-05-02 2019-05-02
US62/842,063 2019-05-02
PCT/US2019/064190 WO2020117772A1 (en) 2018-12-06 2019-12-03 Neurofilament protein for guiding therapeutic intervention in amyotrophic lateral sclerosis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024072811A Division JP2024096258A (ja) 2018-12-06 2024-04-26 筋萎縮性側索硬化症における治療的介入を導くためのニューロフィラメントタンパク質

Publications (3)

Publication Number Publication Date
JP2022513721A true JP2022513721A (ja) 2022-02-09
JPWO2020117772A5 JPWO2020117772A5 (https=) 2022-12-08
JP2022513721A5 JP2022513721A5 (https=) 2022-12-08

Family

ID=68966114

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021531983A Withdrawn JP2022513721A (ja) 2018-12-06 2019-12-03 筋萎縮性側索硬化症における治療的介入を導くためのニューロフィラメントタンパク質
JP2024072811A Pending JP2024096258A (ja) 2018-12-06 2024-04-26 筋萎縮性側索硬化症における治療的介入を導くためのニューロフィラメントタンパク質

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024072811A Pending JP2024096258A (ja) 2018-12-06 2024-04-26 筋萎縮性側索硬化症における治療的介入を導くためのニューロフィラメントタンパク質

Country Status (10)

Country Link
US (1) US12429487B2 (https=)
EP (1) EP3890752A1 (https=)
JP (2) JP2022513721A (https=)
KR (1) KR20210102294A (https=)
CN (1) CN113365640A (https=)
BR (1) BR112021010660A2 (https=)
CA (1) CA3121749A1 (https=)
MA (1) MA54383A (https=)
MX (1) MX2021006548A (https=)
WO (1) WO2020117772A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202006677XA (en) 2018-01-25 2020-08-28 Biogen Ma Inc Methods of treating spinal muscular atrophy
MA54383A (fr) 2018-12-06 2021-10-13 Biogen Ma Inc Protéine neurofilamenteuse pour guider une intervention thérapeutique dans la sclérose laterale amyotrophique
CN115004350B (zh) 2019-06-11 2025-10-28 库力索法荷兰有限公司 利用光学系统特性的调整的分立组件装配体的位置误差补偿
US20230365937A1 (en) * 2020-10-26 2023-11-16 Hadasit Medical Research Services And Development Ltd. Mesenchymal stem cells and their culture
KR200498472Y1 (ko) 2024-05-23 2024-10-24 김민경 경고 또는 안내 문구를 교체형으로 구성시킬 수 있는 배수용 그레이팅

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2790034A1 (en) 2001-06-21 2003-01-03 Isis Pharmaceuticals, Inc. Antisense modulation of superoxide dismutase 1, soluble expression
US20050019915A1 (en) * 2001-06-21 2005-01-27 Bennett C. Frank Antisense modulation of superoxide dismutase 1, soluble expression
SI2548560T1 (sl) 2005-06-23 2015-12-31 Isis Pharmaceuticals, Inc. Sestavki in postopki za moduliranje izrezovanja smn2
WO2008127974A1 (en) 2007-04-13 2008-10-23 The Trustees Of Columbia University In The City Of New York Stem cell-based culture system for drug development
JP5879256B2 (ja) 2009-05-02 2016-03-08 ジェンザイム・コーポレーション 神経変性障害のための遺伝子治療
PT3305302T (pt) 2009-06-17 2018-12-14 Biogen Ma Inc Composições e métodos de modulação de excisões de smn2 em um sujeito
US8465727B2 (en) 2009-10-06 2013-06-18 University of Pittsburgh—of the Commonwealth System of Higher Education Biomarkers for the diagnosis of ALS
CA2872190C (en) 2012-05-09 2024-06-25 Karyopharm Therapeutics, Inc. Nuclear transport modulators and uses thereof
ES2762326T5 (es) 2012-10-15 2023-04-27 Ionis Pharmaceuticals Inc Métodos para modular la expresión de C9ORF72
HK1212597A1 (zh) 2012-10-15 2016-06-17 Isis Pharmaceuticals, Inc. 用於調節c90rf72表達的組合物
WO2014062736A1 (en) 2012-10-15 2014-04-24 Isis Pharmaceuticals, Inc. Methods for monitoring c9orf72 expression
WO2014065341A1 (ja) 2012-10-24 2014-05-01 第一三共株式会社 筋萎縮性側索硬化症治療剤
EP2943225A4 (en) 2013-01-09 2016-07-13 Ionis Pharmaceuticals Inc COMPOSITIONS AND METHODS FOR MODULATING SMN2 DISTRIBUTION IN THE BODY OF A PATIENT
EP4166667A3 (en) 2013-10-11 2023-08-02 Ionis Pharmaceuticals, Inc. Compositions for modulating c9orf72 expression
US20160230172A1 (en) 2013-10-14 2016-08-11 Ionis Pharmaceuticals, Inc. Compositions for modulating expression of c9orf72 antisense transcript
AU2014337506B2 (en) 2013-10-14 2020-10-15 Ionis Pharmaceuticals, Inc. Methods for modulating expression of C9ORF72 antisense transcript
WO2015143245A1 (en) 2014-03-19 2015-09-24 Isis Pharmaceuticals, Inc. Methods for modulating ataxin 2 expression
CN106103717A (zh) 2014-03-19 2016-11-09 Ionis制药公司 用于调节共济失调蛋白2表达的组合物
RS60707B1 (sr) * 2014-04-01 2020-09-30 Biogen Ma Inc Kompozicije za modulaciju ekspresije sod-1
US10024870B2 (en) 2014-04-02 2018-07-17 Wisconsin Alumni Research Foundation Therapeutic and diagnostic methods and compositions for neurodegenerative diseases
WO2015161170A2 (en) 2014-04-17 2015-10-22 Isis Pharmaceuticals, Inc. Compositions and methods for modulation of smn2 splicing in a subject
BR112017004056A2 (pt) 2014-09-12 2017-12-05 Biogen Ma Inc composições e métodos para detecção da proteína smn em um indivíduo e tratamento de um indivíduo
KR20230104759A (ko) 2014-09-30 2023-07-10 뉴리뮨 홀딩 아게 인간-유래의 항-디펩티드 반복체(dpr) 항체
CA3193811A1 (en) 2014-11-14 2016-05-19 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (als)
WO2016112132A1 (en) 2015-01-06 2016-07-14 Ionis Pharmaceuticals, Inc. Compositions for modulating expression of c9orf72 antisense transcript
WO2016167780A1 (en) 2015-04-16 2016-10-20 Ionis Pharmaceuticals, Inc. Compositions for modulating expression of c9orf72 antisense transcript
RS60230B1 (sr) 2015-04-16 2020-06-30 Ionis Pharmaceuticals Inc Kompozicije za moduliranje ekspresije c9orf72
US11260073B2 (en) 2015-11-02 2022-03-01 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating C90RF72
US20190002887A1 (en) 2015-12-31 2019-01-03 Ionis Pharmaceuticals, Inc. Methods for reducing ataxin-2 expression
AU2017248637A1 (en) 2016-04-13 2018-09-27 Ionis Pharmaceuticals, Inc. Methods for reducing C9ORF72 expression
WO2018218219A1 (en) 2017-05-26 2018-11-29 University Of Miami Determining onset of amyotrophic lateral sclerosis
TW201920672A (zh) 2017-08-08 2019-06-01 新加坡商波濤生命科學有限公司 寡核苷酸組合物及其使用方法
TW202413649A (zh) 2017-10-16 2024-04-01 美商航海家醫療公司 肌萎縮性脊髓側索硬化症(als)之治療
SG11202006677XA (en) 2018-01-25 2020-08-28 Biogen Ma Inc Methods of treating spinal muscular atrophy
EA201992364A1 (ru) 2018-04-02 2020-03-23 Кохерус Байосайенсис Инк. АГОНИСТ PPARγ ДЛЯ ЛЕЧЕНИЯ ПРОГРЕССИРУЮЩЕГО НАДЪЯДЕРНОГО ПАРАЛИЧА
BR112020021855A2 (pt) 2018-04-27 2021-02-23 Biogen Ma Inc. anticorpo antirrepetição de dipeptídeo (dpr) (poli-ga) derivado de humanos
WO2020061355A2 (en) 2018-09-20 2020-03-26 Biogen Ma Inc. Serum neurofilament protein for guiding therapeutic intervention in multiple sclerosis
MA54383A (fr) 2018-12-06 2021-10-13 Biogen Ma Inc Protéine neurofilamenteuse pour guider une intervention thérapeutique dans la sclérose laterale amyotrophique
TWI906204B (zh) 2018-12-14 2025-12-01 美商百健Ｍａ公司 用於治療及預防肌肉萎縮性脊髓側索硬化症之組合物及方法
MA54949A (fr) 2019-02-12 2021-12-22 Biogen Ma Inc Biomarqueurs de la leucoencéphalopathie multifocale progressive

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MCCAMPBELL, A. ET AL., J CLIN INVEST, vol. 128, no. 8, JPN6023044167, August 2018 (2018-08-01), pages 3558 - 3567, ISSN: 0005184008 *

Also Published As

Publication number Publication date
CA3121749A1 (en) 2020-06-11
JP2024096258A (ja) 2024-07-12
MA54383A (fr) 2021-10-13
CN113365640A (zh) 2021-09-07
BR112021010660A2 (pt) 2021-08-24
WO2020117772A1 (en) 2020-06-11
EP3890752A1 (en) 2021-10-13
US12429487B2 (en) 2025-09-30
MX2021006548A (es) 2021-09-21
US20220034907A1 (en) 2022-02-03
KR20210102294A (ko) 2021-08-19

Similar Documents

Publication Publication Date Title
JP2022513721A (ja) 筋萎縮性側索硬化症における治療的介入を導くためのニューロフィラメントタンパク質
JP7344337B2 (ja) ミオスタチン阻害剤の使用および併用療法
Finkel Read-through strategies for suppression of nonsense mutations in Duchenne/Becker muscular dystrophy: aminoglycosides and ataluren (PTC124)
Guedes et al. MicroRNA deregulation and chemotaxis and phagocytosis impairment in Alzheimer's disease
US20240158792A1 (en) Composition Comprising Antisense Oligonucleotide and Use Thereof for Treatment of Duchenne Muscular Dystrophy
WO2019236750A2 (en) Targeted treatment of autism spectrum disorder and other neurological or psychiatric disorders
Ravi et al. Genetic approaches to the treatment of inherited neuromuscular diseases
KR102821047B1 (ko) 근위축 측삭 경화증의 치료 및 방지를 위한 조성물 및 방법
JP7665678B2 (ja) 脊髄性筋萎縮症を処置または予防する方法
Wu et al. MiRNA-29a serves as a promising diagnostic biomarker in children with temporal lobe epilepsy and regulates seizure-induced cell death and inflammation in hippocampal neurons
Scott et al. New and emerging drug and gene therapies for Friedreich ataxia
US20250290074A1 (en) Targeted treatment of spliceopathy-induced neurological disorders
Benasutti et al. Efficacy and muscle safety assessment of fukutin-related protein gene therapy
Konieczny Systemic treatment of body‐wide Duchenne muscular dystrophy symptoms
Kwon et al. Analyzing clinical and genetic aspects of axonal Charcot–Marie-Tooth disease
RU2844865C2 (ru) Нейрофиламентный белок для направления терапевтических вмешательств при боковом амиотрофическом склерозе
Yusuf et al. α-synuclein in Parkinson’s disease: a central point of convergence with depression
JP2024511767A (ja) 筋萎縮性側索硬化症の治療
Badina et al. Biomarker Evolution in Pediatric SMA: Insights from CSF pNF-H Dynamics and SMN2 Copy Number During Nusinersen Therapy.
Koller et al. Antagonizing Il10 and Il4 signaling via intracerebral decoy receptor expression attenuates Aβ accumulation
Jennings Common Pathophysiological Features of Charcot-Marie-Tooth Disease
Rastegar et al. Novel homozygous mutation in DYSF gene with limb-girdle muscular dystrophy type 2B through whole exome sequencing in Iran
Mori-Yoshimura et al. DISTAL MYOPATHIES: EP. 71 Long-term evaluation parameters and complications in GNE myopathy: a five-year observational follow-up natural history study
Zhu et al. 360PPolyglucosan body myopathy caused by RBCK1 inversion: a case report
EA047168B1 (ru) Способы лечения или предотвращения спинальной мышечной атрофии

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221130

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221130

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231027

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240125

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240326

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20240517